IATROGENIC AMYLOID ANGIOPATHY AS A NEW CLINICAL PHENOMENON

Background. A literature search of various databases revealed mixed and largely contradictory results regarding the etiology, pathogenesis, prevalence, and diagnostic criteria of cerebral amyloid angiopathies and iatrogenic amyloid angiopathies, which prompted the writing of this literature review.

Aim of the review. To analyze current literature on the etiology, pathogenesis, prevalence, and diagnostic criteria of cerebral amyloid angiopathies and iatrogenic amyloid angiopathies.

Research methods. A comprehensive literature search strategy was developed in PubMed/Medline and the Cochrane Central Trials Register. The search strategy included a randomized control option. Studies were searched from July 2010 to September 2025 without restrictions on the level of evidence or publication status. Both English-language articles and Russian publications were analyzed.

Results. Iatrogenic amyloid angiopathy is a late complication following neurosurgical procedures, primarily involving cadaveric dura mater transplantation in children with traumatic brain injury. Cases of Iatrogenic amyloid angiopathy following cerebral vascular embolization using lyophilized dura mater have been described, as well as a late complication of red blood cell transfusions and growth hormone therapy. Iatrogenic amyloid angiopathy encompasses a wide range of clinical manifestations, from intracerebral hemorrhages with transient neurological impairment to seizure activity. Iatrogenic amyloid angiopathy diagnosis is based on the Boston criteria 2.0 and neuroimaging data.

Conclusion. Despite a significant increase in awareness of Iatrogenic amyloid angiopathy, further study of this nosological entity remains highly relevant. More research is needed to update and expand our understanding of the etiology, pathogenesis, and clinical picture of the disease, and to modify diagnostic criteria for a more accurate clinical diagnosis.

1. Charidimou A., Boulouis G., Frosch M.P. et al. The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI-neuropathology diagnostic accuracy study. Lancet Neurol. 2022;21(8):714-725. https://doi.org/10.1016/S1474-4422(22)00208-3

2. Viswanathan A., Greenberg S.M. Cerebral amyloid angiopathy in the elderly. Ann Neurol. 2011;70(6):871-880. https://doi.org/10.1002/ana.22516

3. Мхитарян Э.А., Фатеева В.В., Камчатнов П.Р. Церебральная амилоидная ангиопатия. Журнал неврологии и психиатрии им. С.С. Корсакова. 2024;124(2):85-90. [Mkhitaryan E.A., Fateeva V.V., Kamchatnov P.R. Cerebral amyloid angiopathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(2):85-90 (In Russ.)]. https://doi.org/10.17116/jnevro202412402185

4. Kaushik K., van Etten E.S., Siegerink B. et al. Iatrogenic Cerebral Amyloid Angiopathy Post Neurosurgery: Frequency, Clinical Profile, Radiological Features, and Outcome. Stroke. 2023;54(5):1214-1223. https://doi.org/10.1161/STROKEAHA.122.041690

5. Pikija S., Pretnar-Oblak J., Frol S. et al. Iatrogenic cerebral amyloid angiopathy: A multinational case series and individual patient data analysis of the literature. Int J Stroke. 2024;19(3):314-321. https://doi.org/10.1177/17474930231203133

6. Vera-Cáceres C., Nersesyan N., Obon M. et al. Iatrogenic cerebral amyloid angiopathy: Two case reports to explore clinical heterogeneity and pathological patterns. J Stroke Cerebrovasc Dis. 2025;34(1):107969. https://doi.org/10.1016/j.jstrokecerebrovasdis.2024.107969

7. Fabjan M., Jurečič A., Jerala M., Oblak J.P., Frol S. Recurrent Intracerebral Haematomas Due to Amyloid Angyopathy after Lyodura Transplantation in Childhood. Neurol Int. 2024;16(2):327-333. https://doi.org/10.3390/neurolint16020023

8. Oblak J.P., Jurečič A., Writzl K., Frol S. Preceding Head Trauma in Four Cases of Sporadic Cerebral Amyloid Angiopathy – Case Report Series. J Stroke Cerebrovasc Dis. 2022;31(2):106260. https://doi.org/10.1016/j.jstrokecerebrovasdis.2021.106260

9. Banerjee G., Samra K., Adams M.E. et al. Iatrogenic cerebral amyloid angiopathy: an emerging clinical phenomenon. J Neurol Neurosurg Psychiatry. 2022:jnnp-2022-328792. https://doi.org/10.1136/jnnp-2022-328792

10. DiFrancesco J.C., Tabaee Damavandi P., Pretnar-Oblak J. et al. Iatrogenic cerebral amyloid angiopathy after red blood cell transfusion? Eur J Neurol. 2024;31(8):e16366. https://doi.org/10.1111/ene.16366

11. Kaushik K., Wermer M.J.H., van Etten E.S. Cerebral amyloid angiopathy decades after red blood cell transfusions: a report of two cases from a prospective cohort. Eur J Neurol. 2024;31(6):e16277. https://doi.org/10.1111/ene.16277

12. Banerjee G., Adams M.E., Jaunmuktane Z. et al. Early onset cerebral amyloid angiopathy following childhood exposure to cadaveric dura. Ann Neurol. 2019;85(2):284-290. https://doi.org/10.1002/ana.25407

13. Collinge J. Mammalian prions and their wider relevance in neurodegenerative diseases. Nature. 2016;539(7628):217-226. https://doi.org/10.1038/nature20415

14. Koemans E.A., Chhatwal J.P., van Veluw S.J., van Etten E.S., van Osch M.J.P., van Walderveen M.A.A., et al. Progression of cerebral amyloid angiopathy: a pathophysiological framework. Lancet Neurol. 2023;22(7):632-642. https://doi.org/10.1016/S1474-4422(23)00114-X

15. Jäkel L., De Kort A.M., Klijn C.J.M., Schreuder F.H.B.M., Verbeek M.M. Prevalence of cerebral amyloid angiopathy: A systematic review and meta-analysis. Alzheimers Dement. 2022;18(1):10-28. https://doi.org/10.1002/alz.12366

16. Sandberg M.K., Al-Doujaily H., Sharps B. et al. Prion propagation and toxicity in vivo occur in two distinct mechanistic phases. Nature. 2011;470:540-542. https://doi.org/10.1038/nature09768

17. Cozza M., Amadori L., Boccardi V. Exploring cerebral amyloid angiopathy: Insights into pathogenesis, diagnosis, and treatment. J Neurol Sci. 2023;454:120866. https://doi.org/10.1016/j.jns.2023.120866

18. Jaunmuktane Z., Brandner S. Invited Review: The role of prion-like mechanisms in neurodegenerative diseases. Neuropathol Appl Neurobiol. 2020;46(6):522-545. https://doi.org/10.1111/nan.12592

19. Jaunmuktane Z., Mead S., Ellis M. et al. Evidence for human transmission of amyloid-β pathology and cerebral amyloid angiopathy. Nature. 2015;525:247-250. https://doi.org/10.1038/nature15369

20. Karatzetzou S., Ioannidis S., Konstantinopoulou E. et al. Iatrogenic Dementia: Providing Insight into Transmissible Subtype of Alzheimer’s Disease, Creutzfeldt–Jakob Disease and Cerebral Amyloid Angiopathy. Biomolecules. 2025;15:522.https://doi.org/10.3390/biom15040522

21. Jaunmuktane Z., Banerjee G., Paine S. et al. Alzheimer’s disease neuropathological change three decades after iatrogenic amyloid-β transmission. Acta Neuropathol. 2021;142(1):211-215. https://doi.org/10.1007/s00401-021-02326-y

22. Panteleienko L., Mallon D., Oliver R. et al. Iatrogenic cerebral amyloid angiopathy in older adults. Eur J Neurol. 2024;31(6):e16278. https://doi.org/10.1111/ene.16278

23. Tanaka F., Umino M., Matsukawa M. et al. Iatrogenic Cerebral Amyloid Angiopathy After Childhood Brain Surgery: Novel Findings of MRI and CT. Neurol Int. 2025; 17:64. https://doi.org/10.3390/neurolint17050064

24. Pollaci G., Potenza A., Gorla G. et al. CSF and Plasma Biomarkers in Patients With Iatrogenic Cerebral Amyloid Angiopathy. Neurology. 2024;103(8):e209828.https://doi.org/10.1212/WNL.0000000000209828

25. Sellimi A., Panteleienko L., Mallon D. et al. Inflammation in Cerebral Amyloid Angiopathy-Related Transient Focal Neurological Episodes. Ann Neurol. 2025;97(3):475-482. https://doi.org/10.1002/ana.27164

26. Panteleienko L., Mallon D., Htet C.M.M., Lizak N. et al. Cerebral Amyloid Angiopathy-Related Inflammation in Iatrogenic Cerebral Amyloid Angiopathy. Eur J Neurol. 2025;32(5):e70198. https://doi.org/10.1111/ene.70198